The latest price target for HUTCHMED (China) (NASDAQ:HCM) was reported by Goldman Sachs on August 1, 2024. The analyst firm set a price target for $19.00 expecting HCM to rise to within 12 months (a possible 14.94% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for HUTCHMED (China) (NASDAQ:HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.

The last upgrade for HUTCHMED (China) Ltd happened on November 24, 2023 when Deutsche Bank raised their price target to $22.1. Deutsche Bank previously had a hold for HUTCHMED (China) Ltd.

The last downgrade for HUTCHMED (China) Ltd happened on September 22, 2021 when Goldman Sachs changed their price target from N/A to $46 for HUTCHMED (China) Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.

While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $17.00 to $19.00. The current price HUTCHMED (China) (HCM) is trading at is $16.53, which is out of the analyst’s predicted range.